Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (GB:0R2M)
LSE:0R2M
Regeneron (0R2M) Share Price & Analysis
1 Followers
0R2M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$689.00 - $998.57
Previous Close$907.5
Volume276.00
Average Volume (3M)997.00
Market Cap
$98.80B
Enterprise Value$90.66B
Total Cash (Recent Filing)$10.84B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)N/A
Beta0.67
Next Earnings
May 02, 2024EPS Estimate
$10.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding109,761,896
10 Day Avg. Volume782
30 Day Avg. Volume997
Standard Deviation0.10
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.95
Price to Sales (P/S)4.18
Price to Cash Flow (P/CF)22.60
P/FCF Ratio28.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.91
Enterprise Value/Gross Profit7.44
Enterprise Value/Ebitda19.32
Forecast
1Y Price Target
$1,041.47Price Target Upside14.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
PremiumStock Analysis & Ideas
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
Bulls Say, Bears Say
Bulls Say
Drug EfficacyDupilumab has shown in-line or better rate reduction and FEV1 improvement compared to Tezepelumab in a population with high eosinophils according to previous asthma studies.
Innovation And StrategyRegeneron's recent patent applications/approvals show the company's longer-term strategy in the obesity metabolic space is beginning to take shape, with a focus on products that offer a superior body composition profile.
Market AdoptionPhysician feedback on Eylea HD has been overall very positive with over 100,000 orders shipped, indicating strong market adoption and support for broader physician prescribing.
Bears Say
Clinical Trial ResultsTezepelumab Ph2 showed a modest exacerbation rate reduction of 17% which is less compared to Dupilumab's 30-34% rate reduction in similar trials.
Drug Approval ProcessThe FDA issued a Complete Response Letter for Regeneron's odronextamab, indicating a delay in potential launch.
Legal IssuesThe Department of Justice filed a complaint alleging REGN fraudulently inflated Eylea's Medicare reimbursement rates.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.19% Other Institutional Investors
98.81% Public Companies and
Individual Investors
0R2M FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest share price was $689.00 and its highest was $998.57 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is May 02, 2024 which is in 9 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 02, 2024. The company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.731 by $1.129.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $10.13.
How many shares outstanding does Regeneron have?
Currently, no data Available
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.86 in its last earnings report, beating expectations of $10.731. Following the earnings report the stock price went down -1.733%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,041.47 (14.76% Upside)
$1,041.47 (14.76% Upside)
Blogger Sentiment
Bullish
GB:0R2M Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $32.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.41%
12-Months-Change
Fundamentals
Return on Equity
16.26%
Trailing 12-Months
Asset Growth
13.18%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
0R2M Company Deck
---
0R2M Earnings Call
Q4 2024
0:00 / 0:00
---
0R2M Stock 12 Months Forecast
Average Price Target
$1,041.47
▲(14.76% Upside)
Technical Analysis
Best Analysts Covering 0R2M
1 Year
1 Year Success Rate
15/19 ratings generated profit
1 Year Average Return
+15.35%
assigned a buy rating 30 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 78.95% of your transactions generating a profit, with an average return of +15.35% per trade.
---